Latest Breaking News On - Oncology stock down - Page 1 : comparemela.com

Wedbush Downgrades Ikena Oncology (NASDAQ:IKNA) to Neutral

Wedbush downgraded shares of Ikena Oncology (NASDAQ:IKNA – Free Report) from an outperform rating to a neutral rating in a research report sent to investors on Wednesday morning, MarketBeat reports. The brokerage currently has $2.00 target price on the stock, down from their previous target price of $8.00. Wedbush also issued estimates for Ikena Oncology’s […]

United statesMarquette asset managementJacobs levy equity management incAcadian asset managementIkena oncology incIkena oncologyFree reportOncology stock downGet free reportLevy equity managementAsset managementVestal point capitalIkena oncology daily

Decheng Capital LLC Acquires New Shares in Pyxis Oncology, Inc (NASDAQ:PYXS)

Decheng Capital LLC Acquires New Shares in Pyxis Oncology, Inc (NASDAQ:PYXS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Commonwealth equity servicesPyxis oncology incJefferies financial groupAcadian asset managementRoyal bankDecheng capitalSchulhoff coPyxis oncologyFree reportEquity servicesAsset managementDecheng capital managementFinancial groupOncology stock downGet free reportPyxis oncology daily

Brokerages Set Cullinan Oncology, Inc (NASDAQ:CGEM) Price Target at $31 00

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year […]

United statesJennifer michaelsonStifel nicolausWilliam blairParkman healthcare partnersSecurities exchange commissionCullinan oncology incAffinity asset advisorsFranklin resources incCullinan oncologyGet free reportExchange commissionAsset advisorsHealthcare partnersTrexquant investmentOncology stock down

Pyxis Oncology, Inc (NASDAQ:PYXS) Receives $8 50 Consensus Target Price from Brokerages

Pyxis Oncology, Inc (NASDAQ:PYXS) Receives $8 50 Consensus Target Price from Brokerages
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Leerink partnrsAcadian asset managementCommonwealth equity servicesSchulhoff coPyxis oncology incRoyal bankJefferies financial groupPyxis oncologyGet free reportMarketbeat ratingsFinancial groupEquity servicesAsset managementDecheng capital managementOncology stock downGet free

Cardiff Oncology s (CRDF) Buy Rating Reiterated at HC Wainwright

Cardiff Oncology s (CRDF) Buy Rating Reiterated at HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerCardiff oncology company profileCallan capitalCardiff oncology incCardiff oncologyFree reportOncology stock downGet free reportPolo like kinaseCardiff oncology daily